Outlook Therapeutics, Inc. financial data

Symbol
OTLK on Nasdaq
Location
Iselin, NJ
Fiscal year end
30 September
Latest financial report
10-Q - Q4 2025 - 17 Feb 2026

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 49% % -38%
Quick Ratio 9.6% %
Debt-to-equity -156% % -7.8%
Return On Equity 293% % 434%
Return On Assets -526% % -326%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 64,114,399 shares 157%
Common Stock, Shares, Outstanding 64,556,570 shares 159%
Entity Public Float $26,900,000 USD -85%
Common Stock, Value, Issued $645,566 USD 159%
Weighted Average Number of Shares Outstanding, Basic 60,205,035 shares 148%
Weighted Average Number of Shares Outstanding, Diluted 60,205,035 shares 148%

Income Statement

Label TTM Value / Value Unit Change %
Revenue from Contract with Customer, Excluding Assessed Tax $1,505,322 USD
Research and Development Expense $21,154,842 USD -55%
General and Administrative Expense $38,646,594 USD 50%
Operating Income (Loss) $58,938,766 USD 29%
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest $20,152,502 USD -145%
Income Tax Expense (Benefit) $2,800 USD 0%
Net Income (Loss) Attributable to Parent $102,860,612 USD -120%
Earnings Per Share, Basic -2.89 USD/shares -17%
Earnings Per Share, Diluted -2.89 USD/shares -17%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value $8,677,424 USD 52%
Accounts Receivable, after Allowance for Credit Loss, Current $114,609 USD
Inventory, Net $3,458,064 USD 11%
Assets, Current $17,166,501 USD 9.6%
Operating Lease, Right-of-Use Asset $212,413 USD -19%
Other Assets, Noncurrent $346,111 USD -17%
Assets $18,238,574 USD 7.2%
Accounts Payable, Current $7,318,649 USD -40%
Employee-related Liabilities, Current $1,554,514 USD 127%
Accrued Liabilities, Current $4,714,026 USD 39%
Liabilities, Current $49,055,800 USD 1.7%
Operating Lease, Liability, Noncurrent $171,988 USD -26%
Liabilities $56,788,039 USD -16%
Retained Earnings (Accumulated Deficit) $628,767,898 USD -20%
Stockholders' Equity Attributable to Parent $38,549,465 USD 23%
Liabilities and Equity $18,238,574 USD 7.2%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities $14,939,111 USD -36%
Net Cash Provided by (Used in) Financing Activities $15,533,450 USD 792%
Common Stock, Shares Authorized 260,000,000 shares 333%
Common Stock, Shares, Issued 64,556,570 shares 159%
Common Stock, Par or Stated Value Per Share 0.01 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect $594,339 USD
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $8,677,424 USD 52%
Deferred Tax Assets, Valuation Allowance $145,880,866 USD 5.1%
Deferred Tax Assets, Gross $145,928,541 USD 5.1%
Operating Lease, Liability $233,113 USD -18%
Lessee, Operating Lease, Liability, to be Paid $275,103 USD -22%
Operating Lease, Liability, Current $61,125 USD 16%
Lessee, Operating Lease, Liability, to be Paid, Year Two $83,680 USD 2.3%
Lessee, Operating Lease, Liability, to be Paid, Year One $81,817 USD 2.3%
Operating Lease, Weighted Average Discount Rate, Percent 0.099 pure 0%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount $41,990 USD -38%
Lessee, Operating Lease, Liability, to be Paid, Year Three $49,447 USD -41%
Deferred Tax Assets, Operating Loss Carryforwards $110,272,674 USD 7.2%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 10,000,000 shares 0%
Unrecognized Tax Benefits $300,000 USD -84%
Lessee, Operating Lease, Liability, to be Paid, Year Four $49,447 USD -41%
Operating Lease, Payments $19,484 USD 0.8%
Preferred Stock, Shares Outstanding 0 shares
Deferred Tax Assets, Net of Valuation Allowance $47,675 USD -38%
Share-based Payment Arrangement, Expense $6,068,626 USD -22%
Preferred Stock, Par or Stated Value Per Share 0.01 USD/shares 0%